Prenatal exposure to antiseizure medications and fetal growth : a population-based cohort study from the Nordic countries

dc.contributor.authorChristensen, Jakob
dc.contributor.authorZoega, Helga
dc.contributor.authorLeinonen, Maarit K.
dc.contributor.authorGilhus, Nils Erik
dc.contributor.authorGissler, Mika
dc.contributor.authorIgland, Jannicke
dc.contributor.authorSun, Yuelian
dc.contributor.authorTomson, Torbjörn
dc.contributor.authorAlvestad, Silje
dc.contributor.authorBjørk, Marte Helene
dc.contributor.authorDreier, Julie Werenberg
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T09:33:13Z
dc.date.available2025-11-20T09:33:13Z
dc.date.issued2024-03
dc.descriptionPublisher Copyright: © 2024 The Author(s)en
dc.description.abstractBackground: The short- and long-term consequences of restricted fetal growth cause considerable concern, and how prenatal exposure to different antiseizure medications (ASMs) affects fetal growth remains uncertain. Methods: This was a population-based cohort study of liveborn singleton children born in Denmark, Finland, Iceland, Norway, and Sweden from 1996 to 2017. Prenatal exposure was defined as maternal filling of prescriptions for ASM during pregnancy registered in national prescription registries and primary outcomes were adjusted odds ratios (aORs) of microcephaly or being born small for gestational age. Findings: We identified 4,494,918 children (males: 51.3%, 2,306,991/4,494,918), including 38,714 (0.9%) children of mothers with epilepsy. In the overall population, prenatal monotherapy exposure with carbamazepine (aOR: 1.25 (95% CI: 1.12–1.40)), pregabalin (aOR: 1.16 (95% CI: 1.02–1.31)), oxcarbazepine (aOR: 1.48 (95% CI: 1.28–1.71)), clonazepam (aOR: 1.27 (95% CI: 1.10–1.48)), and topiramate (aOR: 1.48 (95% CI: 1.18–1.85)) was associated with risk of being born small for gestational age, and carbamazepine was associated with microcephaly (aOR: 1.43 (95% CI: 1.17–1.75)). In children of mothers with epilepsy, prenatal exposure to carbamazepine (aOR: 1.27 (95% CI: 1.11–1.47)), oxcarbazepine (aOR: 1.42 (95% CI: 1.18–1.70)), clonazepam (aOR: 1.40 (95% CI: 1.03–1.89)), and topiramate (aOR: 1.86 (95% CI: 1.36–2.54)) was associated with being born small for gestational age; carbamazepine, with microcephaly (aOR: 1.51 (95% CI: 1.17–1.95)). No associations with small for gestational age and microcephaly were identified after prenatal exposure to lamotrigine, valproate, gabapentin, levetiracetam, phenobarbital, acetazolamide, phenytoin, clobazam, primidone, zonisamide, vigabatrin, ethosuximide and lacosamide, but except for lamotrigine, valproate, gabapentin, and levetiracetam, numbers of exposed children were small. Interpretation: Prenatal exposure to carbamazepine, oxcarbazepine, clonazepam, and topiramate was associated with increased risk of being born small for gestational age in both the overall population and in children of women with epilepsy suggesting that prenatal exposure to these drugs is associated with fetal growth restriction. Funding: The NordForsk Nordic Program on Health and Welfare (83539), the Independent Research Fund Denmark (1133-00026B), the Danish Epilepsy Association, the Central Denmark Region, the Novo Nordisk Foundation (NNF16OC0019126 and NNF22OC0075033), and the Lundbeck Foundation (R400-2022-1205).en
dc.description.versionPeer revieweden
dc.format.extent622196
dc.format.extent
dc.identifier.citationChristensen, J, Zoega, H, Leinonen, M K, Gilhus, N E, Gissler, M, Igland, J, Sun, Y, Tomson, T, Alvestad, S, Bjørk, M H & Dreier, J W 2024, 'Prenatal exposure to antiseizure medications and fetal growth : a population-based cohort study from the Nordic countries', The Lancet Regional Health - Europe, vol. 38, 100849. https://doi.org/10.1016/j.lanepe.2024.100849en
dc.identifier.doi10.1016/j.lanepe.2024.100849
dc.identifier.issn2666-7762
dc.identifier.other219058090
dc.identifier.other5219d32b-f398-4a7a-92c8-508424956a49
dc.identifier.other85186609776
dc.identifier.urihttps://hdl.handle.net/20.500.11815/7501
dc.language.isoen
dc.relation.ispartofseriesThe Lancet Regional Health - Europe; 38()en
dc.relation.urlhttps://www.scopus.com/pages/publications/85186609776en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectAntiepileptic drugsen
dc.subjectBirth weighten
dc.subjectGestational ageen
dc.subjectHead circumferenceen
dc.subjectIn uteroen
dc.subjectPregnancyen
dc.subjectSmall for gestational ageen
dc.subjectInternal Medicineen
dc.subjectOncologyen
dc.subjectHealth Policyen
dc.titlePrenatal exposure to antiseizure medications and fetal growth : a population-based cohort study from the Nordic countriesen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
1-s2.0-S2666776224000152-main_3_.pdf
Stærð:
607.61 KB
Snið:
Adobe Portable Document Format

Undirflokkur